Варианты клинического течения и лечения мерцательной аритмии у больных ИБС по данным проспективного наблюдения
Диссертация
Действие малых доз (0,25 мг внутрь) дигоксина у больных ИБС определяется вариантом клинического течения хронической'(перманентной) МА:. .'¦'< ,• ' при I варианте: уменьшаются продолжительность QT при минимальной ЧЖС и QTdпри II варианте: уменьшаютсямаксимальная ЧЖС и QTd, увеличивается продолжительность интервала RR при максимальной ЧЖСпри III варианте: не изменяются ЧЖС и показатели интервала… Читать ещё >
Содержание
- Список сокращений
- Глава 1. Обзор литературы
Список литературы
- Аверков О.В., Ваулин Н. В. 'Новые тенденции в медикаментозном лечении и профилактике пароксизмальных тахикардии. //РМЖ.- 1997.- 18.- 1162−1176.
- Агеев Ф.Т. Нарушения ритма сердца при поражении миокарда и сердечной недостаточности. //Тер. арх. -1984- 8:147−149
- Антонченко И.В., Савенкова Г. М., Попов С. В. и др. Тактика фармакотерапии пароксизмальной формы фибрилляции предсердий. //Progress in Biomedical Research.- 1999.- 1. 65−69.
- Аржакова Г. С., Фомина И. Г., Ветлужский А. В. Современные принципы лечения мерцательной аритмии с позиции классификации «Сицилианский гамбит». //Кардиоваскулярная терапия и профилактика. — 2002.-1. -68−75.
- Аритмии сердца. Под редакцией В. Дж. Мандела. //М.: Медицина, 1996.- Т. 2. -26−35,39−40,167−190.
- Баум О.В., Попов Л. А., Волошин В. И., Муромцева Г.А. QT-дисперсия: Модели и измерения. //Вестник Аритмологии. — 2000.- 20.- 6−17.
- Баум О.В., Попов Л. А., Волошин В. И., Муромцева Г.А. QT-дисперсия в ортогональных и псев до ортогональных отведениях. //Вестник Аритмологии.-2002.- 26.- 49−56.
- Бойцов С.А., Подлесов A.M. Нарушения ритма сердца при хронической сердечной недостаточности^//Сердечная недостаточность.-2001.-5.- 224−227.
- Болезни сердца и сосудов под редакцией Е. И. Чазова. //М.: Медицина, 1992 — Т. 4. 274−276.
- Вариабельность сердечного ритма. Современная эхокардиография — новые возможности и области применения в клинике. //Московский Медицинский Журнал.- 2000.- 1.-15−19.
- Н.Гарбусенко С. А., Наумов В. Г., Ходжакулиев Б. Т. и др. Влияние дигоксина на желудочковые нарушения ритма у больных с сердечной недостаточностью: взаимосвязь с состоянием симпато-адреналовай системы. //Кардиология,-1992, — 4.-20−24.
- Генденштейн Э.И., Лемкина С. М. Некоторые механизмы развития интоксикации сердечными гликозидами и ее лекарственной профилактики при недостаточности кровообращения. //Кардиология. 1987.- 12.- 107−11.
- Голицин С.П. Лекция. Лечение желудочковых аритмий: поражения и успехи. 2002.
- Гуревич М.А. Хроническая сердечная недостаточность. //М—Медицина — 1997.
- Дабровски А., Дабровски Б., Пиотрович Р. Суточное мониторирование ЭКГ. //Москва, Медпрактика. -1998.- 208 с.
- Дощицин В.Л. Внезапная аритмическая смерть и угрожающие аритмии. //Медафарм холдинг [email protected].
- Дощицин В.Л. Лечение аритмий сердца. //М. — Медицина. — 1993. г
- Дурманов С.С., Бартош Ф. А., Бартош Л. Ф. и др. Изменение центральной гемодинамики у больных мерцательной аритмией после проведения электроимпульсной терапии, //Кардиостим. III. — 1998. — Параграф 32.
- Дурманов С.С., Бартош Л. Ф., Ульков Н. П. и др. Оценка эффективности электроимпульсной терапии в зависимости от некоторых размеров сердца у больных мерцательной аритмией. //Кардиостим. III. — 1998. — Параграф 31.
- Егоров Д.Ф., Лещинский Л. А., Недоступ А. В., Тюлышна Е. Е. Мерцательная аритмия: стратегия и тактика лечения на пороге XXI века. //Ижевск: Алфавит. -1997.-416 с. 21.3ильбер А. П. Синдромы сонного апноэ, — Петрозаводск, 1994.- 184 с.
- Кардиология в таблицах и схемах, под редакцией М. Фрида и С. Грайс- //Практика.1 Москва. 1996.
- Кушаковский М.С. Аритмии сердца. //С.-Петербург: Гиппократ. — 1992.-544 с.
- Кушаковский М.С., Реброва ГА. Опыт длительного амбулаторного применения кордарона для профилактики пароксизмов фибрилляции (трепетания) предсердий. //Кардиология. — 1990. 6. — 54−63.
- Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика). //С-Петербург: Фоллиант.-1999, — 175 с.
- Лещинский Л. А., Тюлькина Е. Е., Гусева Е. Б. и др. Сравнительная эффективность различных антиаритмических препаратов, купирующих фибрилляцию предсердий. //Российский кардиологический журнал. -1997.-5, 21−27.
- Локшин С.Д., Правосудович С. А., Бондаренко О. Б. и др. Терапия вагус-зависимой мерцательной аритмии. // Кардиостим. III. — 1998. — Параграф 211.
- Мазур Н.А. Пароксизмальные тахикардии. //М.: Медицина. 1984.- 149−156.
- Малая Л.Т., Горб Ю.Г.,, Рачинский И. Д. Хроническая недостаточность кровообращения. //Киев: Здоровье. 1994.- 386 — 452.
- Мареев В.Ю. Лечение сердечной недостаточности: инотропная стимуляция или разгрузка сердца? //Кардиология. 1993.- 12.-6.
- Мареев В.Ю., Казей Д. В., Агеев Ф. Т. и др. Влияние периферических вазодилятаторов на нарушения ритма сердца у больных с хронической сердечной недостаточностью. //Кардиология.- 1992.- 4.-30−35.
- Мерцательная аритмия. Под редакцией Бойцова С. А. //С.-Петербург.- 2001.335 с.
- Мухарлямов Н.М. Ранние стадии недостаточности кровообращения и механизмы ее компенсации. //М.: Медицина.- 1978.
- Мухарлямов Н.М. Сердечная недостаточность и нарушения ритма. //Тер. арх.-1987, — 9. -4−8.
- Недоступ А.В. Мерцательная аритмия (Современные аспекты патогенеза, клиники, лечения, прогноза). //Дисс. докт. мед. наук.- М. 1987. — 427с.
- Недоступ А.В. Мерцательная аритмия: современные стратегии и тактики лечения. //РМЖ, — 2001.- 12. 131.
- Недоступ А.В. Парциальный синдром преждевременйого возбуждения желудочков и его значение в патогенезе аритмий сердца. //Тер. арх.- 1978.- 8.24−28.
- Недоступ А.В., Сыркин А. Л., Маевская И. В. О клиническом значении функциональной слабости синусового узла. //Тер. арх.- 1977.- 4. 20 — 26.
- Нестеренко А.Ю., Мазыгула Е. П., Голицын С. П. Принципы лечения желудочковых нарушений ритма у больных с сердечной недостаточностью.// Сердечная недостаточность.- 2001.- Т. 2, — № 5.- С. 236 — 238.
- Остроумова О.Д. Удлинение интервала QT. //Русский медицинский журнал. -2001, — 18.- 750−753.
- Преображенский Д.В., Сидрренко Б. А. Медикаментозное лечение мерцания предсердий. //Москва. 2003. — 368с.
- Рекомендации Американского Кардиологического Колледжа, Американской ассоциации Сердца и Европейского Общества Кардиологов по лечению пациентов с фибрилляцией предсердий. //. Am. Coll. Cardiol. 2001.- 4. -1266
- Рябыкина Г. В., Соболев А. В. Вариабельность ритма сердца. //М.: СтарКо. -1998.-200 с. I
- Сидоренко Б.А., Преображенский Д. В. Диагностика и лечение хронической сердечной недостаточности. //Москва. — 2001- часть первая.- 115 с.
- Сидорова Л.Д., Архипова Г. Ф., Куделя A.M. и др. Комплексная оценка эффекгивности лечения легочно-сердечной недостаточности дигоксином под контролем определения его концентрации в плазме крови. //Тер. арх. —1987. — 10. 47−51.
- Соломахина Н.И. Особенности функции левого желудочка и левого предсердия у больных ишемической болезнью сердца, осложненной пароксизмальной формой мерцательной аритмии. //Дисс. канд. мед. наук. М. -1991.-С. 151.
- Сумароков А.В., Михайлов А. А. Клиническая электрокардиография. //М.г, 1. Медицина. 1975. — 200 с.
- Сумароков А.В., Михайлов А. А. Аритмии сердца. //М.— Медицина—1976. — 215 с.
- Фишер А.А., Наурбиева Е. Н. Особенности центральной и вегетативной регуляции сердечного ритма в покое и после приема пищи у больных с сочетанием ишемической болезни сердца и язвенной болезнью двенадцатиперстной кишки. //Кардиология. 1990.- 12. —30.
- Явелов И.С. Особенности лечения мерцательггой аритмии. // РМЖ.- 1998.18, — 1160−1169.
- Якубович И.И. Связь между увеличением размеров левого и (или) правого предсердий и возникновением пароксизмов фибрилляции (трепетания)• Iпредсердий (клинико-эхокардиографическое исследование). //Дисс. канд. мед. наук, — СПБ.- 1994.- 129 с.
- ACC/AHA/ESC guidlines for the managemnt of patients with atrial fibrillation. //Eur Heart J. 2001. — 22. — 1852−1923.
- Alessie M.A., Konings K., Kirchhof C. Mapping of atrial fibrillation. //In: Olsson S.B., Allessie M.A., Campbell R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk, NY: Futura Pub. 1994. -37−49.
- Allessi R., Nisynowitz M., Abildskov J.A., Moe’J.K. Nonuniform distribution of vagal effects on the atrial refractory period. //Am. J. Physiol.- 1958.- 194.- 406.
- Allessie M.A., Rensma P.L., Brngada J. et al. Pathophysiology of atrial fibrillation. //In: Zipes D.P., Jalife J., and eds. Cardiac, electrophysiology from cell to bedside.-Philadelphia: W.B. Saunders.- 1990.- 548−559.
- Amiodarone Versus Sotalol Study Group. Multicenter randomized trial of sotalol versus amiodarone for chronic malignant ventricular tachyarrhythmia. //Eur. Heart J. 1989, — 10.- 685−694.
- Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of dl-sotalol for suppression of chronic ventricular arrhythmias. //Am J Cardiol. — 1991. — 67. —511.
- Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. //J Am Coll Cardiol.- 1990. -15.- 698.
- Anttila M., Arstila M., Preffer M., Tikkanen R., et al. Human pharmacokinetics of sotalol. Acta Pharmacol. //Toxicol.- 1976.- 39.- 118−128.
- Antz M, Cappato R, Kuck KH. Metoprolol Versus sotalol in the treatment of sustained ventricular tachycardia. //J.' Cardiovasc Pharmacol.- 1995.- 26.- 627−635.
- Aronow W.S., C., Kronzoon I., Gutstein H. Risk factors for new tromboembolici, stroke in patients 62 years of age with chronic atrial fibrillation. //Am. J. Cardiol. — 1998.- 82.- 119−121.
- Atwood J.E., Myers J., Sandhu S., et al. Optimal sampling interval to estimate heart rate at rest and during exercise in atrial fibrillation. //Am J Cardiol.—1989.-63.-45−48.
- Beasley R., Smith D.A., McHaffie D. J. Exercise heart rate at different serum digoxin concentrations in patients with atrial fibrillation. //Brit. Med. J. 1985. — 290.- 9−11.
- Bellandi F., Dabizzi R.P., Niccoli L., et al. Propafenone and sotalol: long term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. //Ital Cardiol. 1996.- 26. — 379−390.
- Benditt D.G., Williams J.H., Jin J. et al. Maintenance of sinus rhythm with oral d, l-soptalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. //Am. J. Cardiol.- 1999, — 84.- 270−277.
- Benjamin E.J., Levy D.,' Vasiri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham study. //JAMA. —1994. -271. -840−844.
- Bharti S., Lev M. Histology of the normal and diseased atrium. //In: Falk R.H., Podrid P.G., editors. Atrial Fibrillation: Mechanism and Management. New York: Raven Press, -1992. 15−39.
- Bialy D., Lehmann M.N., Schtimacher D.N. et al. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. //JACC. 1992. — 19. — 41A.
- Bjork U., Karesoja M., Hirvonen P. Effective cardioversion in the elderly. //In Olsson S.B., Allessie M.A., Campbell R.W.F editors Atrial Fibrillation: mechanisms and therapeutic strategies. Armonk, NY. 1994. — 343−347.
- Botto G.L., Politi A., Bonatti R. et al. External cardoiversion of atrial fibrillation: a prospective study of predictive of technical and clinical failure. //Eur. H.J. — 1998. -19.-3672.
- Bowels I., Zamfers E., Majo M., Hertzberger D. How effective is electrical cardioversion in the long run? // Abstr. of XVIII-th Congress of Europ. Soc. Card.// Eur. H. J. 1996. — 17. — Abstr. Suppl.- 492.
- Brachmann J., Schmitt C., Beyer T. et al. Heart failure and Arrhythmias. //Wurzburg. 1990.
- Brand F.N., Abbott R., Kammel W.B. ey al. Characteristics and prognosis of lone atrial fibrillation: 30-years follow up. In the Framigham Study. //JAMA. -1985. -254. 3449−3453.
- Breihardt G., Camm A.G., Campbell R.W.F., et al. by Members of the Sicilian Gambit Antiarrythmic Therapy: A Pathophysiologic Approach. //Armonk. — NY. -Futura Pub. -1994. г 3−85: 155−193.
- Brugada R. Familial form of atrial fibrillation. //In: Atrial fibrillation: a practical approach. Ed. J. Brugada. Prous Science. — Barcelona. — Spain. — 2000. — 65−69.
- Brugada R., Tapscott Т., Czernuszewicz G.Z., et al. Identification of a genetic locus for familial atrial fibrillation. //N Engl J Med. 1997. — 336. -905−911.
- Buser P.T., Pfisterer M.E., Kiowski W., et al. QTc-dispersion: a powerful predictor of successful amiodarone therapy in complex ventricular postinfarct arrhythmias. //Eur. Heart J.- 1995.-16.- Suppl. Abstr. 711.
- Campbell R.W.F. Atrial fibrillation: management with class Ic drugs. //In: Olsson S.B., Allessie M.A., СатрЬеЦ R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk, NY: Futura Pub. -1994. -273−286.
- Campbell T. J, Gavaghan T. P, Morgan J.J. Intravenous sotalol for the treatment of atrial flutter after cardiopulmonary bypass. //Br. Heart J 1985.- 54.- 86−90.
- Capucci A. Recent Atrial Fibrillation trials — Clinical consequences. //European Society of Cardiology XXTV" Congress August 31 — September 4, 2002 Berlin — Germany. Atrial fibrillation today: recent therapeutic achievements.
- Cappucci A, Boriani G., Rubino I., et al. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. //International Journal Circulation. — 1990. 82. -1106.
- Carlsson J., Miketic S., Windetler J., et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. //J Am Coll Cardiol. 2003. — 41. — 1690−1696.
- Chen P. S., Prystowsky E.N. Role of concealed and supernormal conductions during atrial fibrillation in the preexcitation syndrome. //Am. J. Cardiol.-l 991.-68.-1329−1334.
- Chen S.A., Tai C.T., Yu, W.C., et al. Right atrial focal atrial fibrillation: electrophysiologic characteristics and radio frequency catheter abblation). //J Cardiovasc Electrophysiol. 1999. — 10. -328−335.
- Chesalviel-Guilbert F., Davy J.M., Poirier J.M. et al. Mexiletine antagonizes effects of sotalol on QT interval duration and its ptoarrhythmic effects in a canine model of torsades de pointes. //J. Am. Col. Cardiol.- 1995.- 26.- 787−792.
- Cheung D.W. Electrical activity in the pulmonary vein and its interaction «with the right atrium in the guinea-pig. //J Physiol (Lond). 1981. — 314. -445−456.
- Choro F.J., Kirchhof C.J., Brugada J., Allessie M.A. Ventricular response duringirregular atrial pacing and atrial fibrillation. //Am. J. Physiol.-1990.-259.-Hl015i1. H1021.
- Cobbe S. Atrial Fibrillation and quality of life. //European Society of Cardiology XXIV Congress August 31 — September 4, 2002 Berlin G. ermany Atrial fibrillation today: recent therapeutic achievements.
- Coudevenos J., Vakalis J., Lathnidon A. et al. Epidemiology of paroxysmal atrial fibrillation. //Eur. Heart J. -1996. 17. — 1146.1.,
- Coumel P. Autonomic arrhythmogenic factors in paroxysmal atrial fibrillation. //In: Olsson S.B., Allessie M.A., Campbell R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk, NY: Futura Pub. -1994, -171−185.
- Coumel P. Neural fibrillation. //In Falk R.H., Podrid P.J., editors. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press.—1992. -109−125.
- Coumel P. Paroxysmal AF a disorder of autonomic tone? //Eur. H. J. 1994.- 15 (Suppl. A).- 9−16.
- Coumel P., Hermida J.S., Wennerblom В et al. Heart rate variability in myocardialhypertrophy and heart failure, and the effects of beta-blocking therapy. A nonspectrali, analysis of heart rate’oscillations. //Eur. H. J.- 1991.- 12.- 412.
- Coumel P., Leclercq J.F., Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. //Am. J. Cardiol.-1984.- 54D.- 60−66.
- Coumel Т., Thomas O., Leenhardt A. Drug therapy for prevention of atrial fibrillation. //Am J Cardiol. -1996. 77. -3A-9A.
- Crijns H.J.G.M., Gosselink A.T.M., van Gelder I.C. et al. Drugs after cardioversion to prevent relapses of atrial fibrillation. Atrial fibrillation, a treatable disease? //Dordrecht: The Netherlands: Kluwer Academic Publishers- 1992.- 105 148.
- Crijns H.J.G.M., Gosselink A.T.M., Ruda M.Y., et al. Superiority of ibutilide over d-sotalol in termination of atrial fibrillation and flutter: results of multinational trial. // Eur H. J.- 1996.- 17 Suppl.- Abstr. P. 3155. ,
- Dahlstorm C.D., Edvardsson N., Nasheng C., Olsson S.B. Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation. //Clin. Cardiol. 1992. — 15.-280−284.
- Darian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humans. /-/Am. J. Cardiol.- 1993.- 72. 72A- 79A.
- Darian P., Newman D., Harris L., Downar E. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone. //Can. J. Cardiol. -1994.- 10.- 193 -200.
- Darian P., Paquette M., N. ewman D., et al. Quality of life improves following treatment in the Canadian Trial of Atrial Fibrillation (abstr). //Circulation. — 1999. -100 (Suppl I). -1−502.
- Darian P., Paquette M.,'Newman D. et al. Quality of life’improves with treatment in the Canadian Trial of Atrial Fibrillation. //Am Heart J. 2002. — 143. -984−990.
- Day C.P., McComb J.M., Campbell R.W.F. QT dispersion: an indication of arrhythmia rise in patients with long QT intervals. //Br Heart J.- 1990.- 63.- 342−344.
- Dittrich H.C., Pearce L.A., Asinger R.W., et al. For the Stroke prevention in Atrial Fibrillation Investigators. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. //Am Heart J. 1999. — 137. — 494−499.
- Evans W., Swanri P. Lone auricular fibrillation. //Br. Heart J.-l954.-16.-189−194.
- Falk R.H. Atrial fibrillation. //In book: Cardiac Arrhythmia. Ed. Podrid P.J., Коwey P.R., Williams Wilkins, Baltimore. 1995. — 803−828.
- Fei H., Frame L.H. d-Sotalol terminates reenrty by two mechanisms with different dependence on the duration of the excitable gap. //J. Pharmacol. Exp. Ther. 1996.277.- 174−185.
- Feinberg W.M., Seeger J.F., Carmody R.F., et al. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial.fibrillation. //Arch Intern Med. -1990. 150. — 2340−2344.
- Flegel K.M., Shipley M.J., Rose G. Risk of stroke in none-rheumatic atrial fifbrillation. //Lancet. 1987. — 1. — 526−529.
- Fomina I.G., Dovgolis S.A., Kozlov E.A. Lack of correlation between existence of atrial fibrillation and left atrial dilatation. //Journal Amer. College Cardiol. — 1998. -31.-5 (suppl. C). abstr. 991.
- Francisco G. C. Intra-atrial conduction and atrial fibrillation. //In Olsson S.B., Allessie M.A., Campbell R, W., editors. Atrial (Fibrillation: mechanisms and therapeutic strategies. Armonk, NY. — 1994. — 51 -65.
- Franz M.R. The role of monophasic action potential recording in atrial fibrillation. //In: Olsson S.B., Allessie M.A., Campbell R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk. — NY. — Futura Pub. — 1994. — 109 -125.
- Frey В., Heinz J., Binder Т., et al. Diurnal variation of ventricular response to atrial fibrillation in patients with advanced heart failure. //Am Heart J. — 1995. —129. 58−65.
- Frost L., Engholmf G., Holterf S., Husted S. Decrease in mortality in patientsiwith hospital diagnosis of atrial fibrillation in Denmark during the period 1980−1993. //Eur. H.J.-1999.- 10.-21.
- Frustaci A., Chimenti G, Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. //Circulation. 1997. — 96. -1180−1184.
- Furberg C.D., Psaty B.M., Manolio T.A., et al. Prevalence of atrial fibrillation in elderly subjects (the cardiovascular Health Study). //Am J Cardiol. — 1994. — 74. -236 -2341.
- Furlanello F., Stefenelli C. Regimens for the pharmacologic management of arrhythmia. //Italy.- 2000, — 65.
- Gage B.F., Cardinalli A.B., Owens D.K. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. //Arch Intern Med. 1996. -156. — 1829−1836.
- Gallik D.M., Kim S.J., Ferrick K.J. et al. Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. //Am. Heart J.- 1997- 134.- 155−160.
- GUI J.S., Mehta D., Ward.D.E., Camm A.J. Efficacy of flecainide, sotalol and veraparrdl in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. //Br. Heart J.- 1992.- 68 (4).- 392−397.
- Gray R.A., Pertsov A.M., Jalife J. Incomplete reentry and epicardial breakthrough patterns during atrial fibrillation in the sheep heart. //Circulation. — 1996. — 94. -2649−2661.• i
- Haissagueri M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation treated by ectopic beats originating in the pulmonary veins. //N Engl J Med. — 1998. -339.- 659−666.
- Halinen MO, Hutunen M, Paakinen S, Tarssanen L. Comparison of sotalol withi digoxine-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the
- Sotalol Digoxine Quinidine Trial). //Am. J. Cardiol.- 1995, — 76.- 495−498.
- Han J., Мое G.K. Nonuniform recovery of excitability in ventricular muscle. //Circ Res.-1964.-14.- 44−60.
- Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. //Ann Intern Med. — 1999. — 131. 688−695.
- Но K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. //J. Am. Cardiol. 1993. — 22. — 6A.
- Ho D.S., Zecchin R.P., Richards D.A., et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. //Lancet. 1994.- 344, — 18−23.
- Hoffman A., Kappenberger L., Jost M., Burchardt D. Effect of amiodarone on sinus node function in patients with sick sinus syndrome. //Clin. Cardiol. — 1987. -10. 451−452.
- Hohnloser S.H., Klingenheben Т., Zabel M., Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. //Am. J. Cardiol. 1993, — 72 (4).- 67A-71A.
- Hohnloser S.H., Kuck K.H. Atrial Fibrillation: maintaining sinus rhythm versus ventricular rate control: the PIAF trial: Pharmacological Intervention in Atrial Fibrillation. //J Cardiovasc Electrophysiol. 1998. — 9. — S121−126.
- Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial.//Lancet.-2000.-356.- 1789−1794. ' .
- Hohnloser S.H., van de Loo, Baedeker F. Efficacy and proarrythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidne. //J Am Coll Cardiol. 1995. — 26. — 852−858.
- Hohnloser S.H., van de .Loo A., Kalusche D. et al. QT dispersion before and after sotalol: is it a useful tool for the prediction of drug effectiveness or proarrhythmic risk? //Eur. H. J.- 1994.- 15.- Suppl. Abstr.- A 171−179.
- Homestam В., Held P. Natural history of acute’atrial fibrillation. //Eur. H J. -1996. 17.- 1147.
- Janse M.J. The role of the atrioventricular node in atrial fibrillation. In: Olsson S.B., Allessie M.A., Campbell R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk. — NY. — Futura Pub. — 1994. -127−140.
- Jenkins LS and the AFFIRM Investigators. AFFIRM Functional Study and Quality of Life Substudy. //NASPE 23rd Annual Scientific Sessions, San Diego, California 11th May 2002.
- Jordaens L. Short and long term consequences of paroxysmal and chronic atrial fibrillation. //Eur. J.C.P.E. -1996. 8. — 32.
- Jovie A., Troskot R., Neric-Boreilo M. Pulsed Doppler evaluation of atrial mechanical function after pharmacological cardioversion of atrial fibrillation. //Eur. H.J. 1996, — 17. — Abstr. Suppl.- 202.
- Julian D.G., Jackson F.S., Prescott R.J., Szekely P. Controlled trial of sotalol for one year after myocardial infarction. //Lancet. — 1982. 2. — 1142−1147.
- Juul-Moller S., Edvardsson N., Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. //Circulation. 1990. — 82. — 1932.
- Kaein H.O., Kaplinsky E. Verapamil and digoxin: their respective effects on atrial fibrillation and their interaction. //Amer. J. Cardiol. 1982. — 50. — 894−902.
- Kali J.G., Kopp D.E., Jain S. et al. Sotalol versus low-dose amiodarone for maintenance of sinus rhythm in patients with atrial fibbrillation (abstract). //JACC.-1996.- 27.- 706A.
- Kalusche D., Stockinger J., Betz P., Roscamm H. Sotalol and quinidne/verapamil (cordichin) in chronic atrial 'fibrillation: conversion and 12-month follow-up: a randomized comparison (in German). //Z Cardiol. — 1994. 83 (suppl 5). — 109−116.
- Kamp O., Verhorst P.M., Welling R.C. et al. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. //Eur. H. J.- 1998, — 20.- 979−985.
- Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Coronary heart disease and atrial fibrillation: The Framingham study. //Am Heart J. 1983. — 106. — 389−96.
- Katz A.M. Cardiomyopathy of overload m^jor determinant of prognosis in congestive heart failure. //New Engl. J. Med.- 1990.- 322−100−109.
- Kehoe R.F., MacNeil D.J.,'Sheutlin T.A., et al. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmetic agents. //Am. J. Cardiol. 1993. — 72.- 56A.
- Kempster P.A., Gerraty R.p., Gates P.C. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. //Stroke. 1988. — 19. — 955−957.
- Khan I.A. Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.'//Am Heart J. 2002. — 144. — 11−22.
- Klingenhegen Т., Hohnloser S.H. Effect of sotalol on heart rate variability in patients with symptomatic, complex ventricular arrhythmias. //Z. Kardiol.- 1994.- 83 (4).- 293−298.
- Koch K.Th., Duren D.R., van Swieten P. A long term efficacy and safety of d-Sotalol in patients with ventricular tachycardia and low ejection fraction. //Eur. H. J.- 1995.- 16.- Suppl. Abstr. 2555.
- Konings K.T., Kirchhof C.J., SmeetsJ.R., et al. High density mapping of electrically induced atrial fibrillation in humans. //Circulation.-l994.-89.- 1665−1680.
- Kopekcy S.L., Gersk B.J. McGoon M.D. et al. The natural history of lone atrial fibrillation. A Population-based study over three decades. //N. Engl. J. Med. —1987. -317. 669−674.
- Koskinen P., Kupari M. The role of alcohol in atrial fibrillation. //In: Olsson S.B., Allessie M.A., Campbell R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk. — NY. — Futura Pub. — 1994. — 225−236.
- Kottkamp H., Haverkamp W., Borggreffe M., Breithadt G. The role of class IIIantiarrhythmic drugs in atrial fibrillation. In: Olsson S.B., Allessie M.A., Campbellf
- R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. — Armonk.- NY. Futura Pub. — 1994. — 287−306.j
- Krahn A.D., Manfreda J., Tate R.B., et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. //Am. J. Med. 1995. — 98. — 476−484.
- Kuhlkamp V., Mewis S., Mermi J. et al. How to identify patients at risk for torsades de pointes during treatment with D/L sotalol. //Eur. H. J.- 1994.- 15,-Suppl. Abstr. 2041.
- Kuhlkamp V., Mewis S., Suchalla R. et al. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. //Eur. H. J.- 1996.- 17.- Suppl. Abstr. 2583.
- Kumagai К., Khrestian С., Waldo Al. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: insights into the mechanisms of its maintenance. //Circulation. — 1997. — 95. 511−521.
- Langendorf R., Pick A.L., Katz L.N. Ventricular response in atrial fibrillation: roleof concealed conduction in the AV junction. //Circulation. — 1965. — 32. 69−75.1 i
- Lazzara R. Antiarrhythmic drugs and torsades de pointes. //Eur. Heart J. —1993. -14 (suppl. H). 88−92.
- Lazzara R. From first class to third class: recent upheavalin antiarrhythmic therapy lessons from clinical trials. //Am. J. Cardiol. — 1996. — 78. — 28−33.
- Lee S.H., Chen S.A., Tai C.T. et al. Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation. //Am. J. Cardiol.- 1997.- 79 (7).- 905−908.
- Lee K.W., Kligfield P., Dower G.E., Oldri P.M. QT dispersion, T-wave projection, and heterogeneity of repolarization in patients with coronary artery disease. //Am. J. Cardiol. 2001.- 87.- 148−151.
- Lee R.J., Wong M., Siu A., et al. Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. //Am. Heart J.-1996.- 132 (5).- 973−978.
- Levy S., Maarek M., Coumel P. et al. for the College of French cardiologists. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. //Circulation. 1999. — 99. — 3028−3035.
- Levy M.N., Yang Т., Walik D.W. Assessment of beat-by-beat control of heart rate by the autonomic nervous system: molecular biology techniques are necessary, but not sufficient. //J. Cardiovasc. Electophysi’ol. 1993. — 4. — 183.
- Lewis R.V. Atrial Fibrillation. The therapeutic options. //Drugs. 1990. — 40 (6). -841−853.
- Lewis R., Irvine N., McDevit D.G. Relationships between heart rate, exercise tolerance, and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil, and diltiazem. //Ibid. 1988. — 9. — 777−781.
- Lewis R., Lakhani M., Moreland T. A., MeDevit D.G. A comparison of verapamil and digoxin in the treatment of atrial fibrillation. //Eur. H.J. 1987. — 8. — 148−153.
- Li D., Fareh S., Leung Т.К., Nattel S. Promotion of atrial fibrillation by heart faHure in dogs: atrial remodeling of a different sort //Circulation.—1999—100.-87−95.
- Lundstrom Т., Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. //J. Amer. Coll. Cardiol. 1990. — 16. — 86−90.
- Mackstaller L. L., Alpert J.S. Atrial fibrillation review of mechanism, etiology, and therapy. //Clin. Cardiol. -4997. 20. — 640−650.
- MacNeil D.J., Davies R.O., Beichman D. Clinical safety profile of sotalol in the treatment of arrhythmias. //Amer. J. Cardiol. 1993. — 72. — 44 °F.
- Maixent J. M., Paganelli F., Scaglione J., Levy S. Antibodies against myosin in sera patients with idiopathic paroxysmal atrial fibrillation. //J Cardiovasc Electrophysiol. -1998.-9. -612−617.
- Mandell W.J. Cardiac.arrhythmias. Their, mechanisms, diagnoses and management //Philadelphia. Toronto. — 1980. — 680 p.
- Matsuda Y., Yamagushi Т., Takahashi N. et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. //Cardiovasc. Res. 1991. — 25. — 453−457.
- Mazgalev Т., Dreifus L.S., Bianch J., Michelson E.L., Atrioventricular nodaliconduction during atrial fibrillation in rabbit heart. //Am J Physiol. 1982. — 243. -H754−760.
- Michelucci A., Padeletti L., Porciani M.C. et al. Dispersion of refractoriness and atrial fibrillation. //In: Olsson S.B., Allessie M.A., Campbell R.W., Atrial Fibrillation: Mechanisms and Therapeutic $trategies.-Armonk.-NY.-Futura Pub.-1994- 81−108.
- Мое G.K., Abildskov J A. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. //Am Heart J. 1959. — 58. — 59−70.
- Мое G.K., Abildskov J.A. Observation of the ventricular dysrhythmia associated with atrial fibrillation in the dog heart. //Circ Res. 1964. -4. -447−460.
- Morris D.C., Hurst J.W. Atrial fibrillation. //Curr. Probl. Cardiol. 1980.-5.-1−51.
- Murgatroyd F.D., Gibson S.M., Baijan X., et al. Double-blind-placebo-controlledtrial of digoxin in symptomatic paroxysmal atrial fibrillation. //Circulation. 1999. —i99. 2765−2770.
- Myers M, Peter T, Weiss D, et al. Benefit and risk of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. //Am Heart J. 1990. — 119. — 8.
- Navasio A., Modena M., Chesi C., et al. Effect of pharmacologic versus electrical cardioversion of chronic atrial fibrillation on left atrial function. //Eur. H. J. 1996. -17.-3151.
- Ninomyia F. Direct evidence of nonuniform distribution of vagal effects on dog atria. //Circ. Res.- 1966.- 19.- 576.
- Nolte C. W. Т., Jost S., Miige A., Daniel W. G. Protection from digoxin induced coronary vasoconstriction in patients with coronary artery disease by calcium antagonists.// Am. J. Cardiol- 1999.- Vol. 83, — P. 440−442.
- O’Hare M.F., Leahey H., Murnaghan G.A. et al. Pharmacokinetics of sotalol during pregnancy. //Eur. J. Clin. Pharmacol.- 1983.- 24.- 521−524.
- Otsuka 1С, Ikari’M., Ichimaru Y. et al. Experimental study on the relationship between cardiac arrythmias and sleep states ambulatory ECG-EEC monitoring. //Clin. Cardiol.- 1986.- Vol. 9.- P. 305 313.
- Page R.L., Tang A.S., Prystowsky E.N. Effect of continuous enhanced vagal tone on atrioventricular node and sinoatrial nodal function in humans. //Circ Res. 1991. — 68. — 1614−1620.
- Page R.L., Wharton J.M., Prystowsky E.N. Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. //Am J Cardiol. 1996. — 77. — 260−265.
- Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation to rhythm management: the AFFIRM study design. //Am J Cardiol. 1997. — 79. — 1198−1202.
- Podrid P.J. Atrial Fibrillation: Mechanisms and Management. //New York. -Raven Press. 1992. — 109−125.
- Promfert S.M., Beasley C.R.W., Challenor V., Holgate S.T. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. //Clin. Sci. 1988.-74.- 351−357.
- Protheroe J., Fahey Т., Montgomery A.A., Peters T.J. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analyses. //BMJ. 2000. — 320. — 1380−1384.
- Prystowsky E.N., ICatz A.M. Atrial Fibrillation. //In Topol E.S., editor. Textbook of Cardiovascular Medicine. Philadelphia. — Lippincott-Raven. — 1998. — 1827−1861.
- Rawles J.M. What is meant by a «controlled» ventricular rate in atrial fibrillation? //Br Heart J. 1990. — 63.'- 157−161.
- Rawles J.M., Malcolm J., Metcalfe K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. //Br. Heart J. -1990. 63. — 225−227.
- Reiffel J.A. International consensus on atrial fibrillation management. //Heart rate disease. New trend in research, diagnosis and treatment. Editor Asher Kimchi. -Washington, DC, USA, 2001, — Medimond.- 613 — 621.
- Reimold SC, Cantillon CO, Friedman PL et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrilation. //Am J Cardiol. 1993. — 71. -558. ' •
- Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analyses of pooled data from five randomized controlled trials. //Arch Intern Med. -1994. 154. — 1449−1457.
- Roden DM. Usefulness of sotalol for life threatening, ventricular arrhythmias. //Am. J. Cardiol. 1993. — 72 (4). — 51A- 55A.
- Rubart M., Zipes D.P. Genesis of cardiac arrhythmia: electrophysiological considerations. //In: Brounwald E., Zipes D.P., Libby P. Heart Disease. Philadelphia: W.B. Saunders 2001- 659−700.
- Sager P.T. Atrial fibrillation: antiarrhythmic therapy versus rate control withantitrombotic therapy. //Am. J. Cardiol. 1997. — 80 (80A). — 74G-81G.i ,
- Scardi S., Mazzone C., Pandullo C. et al. Lone atrial fibrillation: prognosticdifferences between paroxysmal and chronic forms after 10 years of following up. //Am. Heart J. 1999. — 137. — 686−691.
- Schlep per M. Control of ventricular rate in atrial fibrillation: role of autonomous nervous system. //Editor Haessle AB.- Atrial Fibrillation. Sweden. -1982.-307−318.
- Seidi K., Hauer В., Schwik N. et al. Comparative efficacy of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of an cardioverter defibrillator. //Eur. Heart J.- 1995.- 16.- Suppl. Abstr. P1267.
- Seidi K., Hauer В., Schwik N. et al. Efficacy, safety and usefulness of acute pharmacological cardioversion of persistent atrial fibrillation with amiodarone. //Eur. J. С. P. E. 1996. — 6. — 153−157.
- Singth B.N. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. //Eur. Heart J. 1993. — 14 (suppl H): 14−23.
- Singth B.N. Controlling cardiac arrhythmias: an overview with historical perspective. //Am. J. Cardiol. 1997. — 80 (80A). — 4G — 15G.
- Smith T.W., Antman E.A., Friedman P., et al. Digitalis glicosides: mechanisms and manifestations of toxicity. //Prog. Cardiovasc. Dis. 1984. — 26. — 495 — 523.
- Smith T.W., Antman E.A., Friedman P., et al. Digitalis glicosides: mechanisms and manifestations of toxicity. //Prog. Cardiovasc. Dis. 1984. — 27. — 21 — 56.
- Smith W.M., Lubbe W.F., Whitlock R.M., et al. Long-term tolerance of amiodarone treatment for cardiac arrhythmias. //Am J Cardiol. — 1986. 57. — 1288.
- Soyka L.F., Wirtz C., Spangenberg R.B. Clinical safety of sotalol in patients with arrhythmias. //Am J Cardiol. 1990. — 65. — 74A.
- Spach M.S., Barr R.C., Jewett P.H. Spread of excitation from the atrium into thoracic veins in human beings and dogs. //Am J Cardiol. 1972. — 30. — 844−854.
- Steads R. P., English K., Birchali A. et al. The therapeutic efficacy of atenolol compared to sotalol in treatment of paroxysmal atrial fibrillation. //Eur. H.J. — 1998. -19.-363. Par. 2038.
- Stein K.M., Borer J.S., Hochreiter C., et al. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. //Am J Cardiol. 1994. — 74. — 906−911.
- Stroke Prevention in Atrial Fibrillation Study: final results. //Circulation. 1991. — 84. — 527−539.
- Van Den Berg M.P., Crijns H.J., Haaksma J., et al. Analyses of vagal effects on ventricular rhythm in patients with atrial fibrillation. //Clin Sci.-1994. 86.-531−535.
- Van Den Berg M.P., Haaksma J., Brouwer J. et al. Heart rate variability in patients with atrial fibrillation is related to vagal tone. //Circulation.-1997.- 96.- 1209 1216.
- Waktare J.E.H., Camm A.J. Atrial fibrillation begets trouble. //Heart.-1997.- 77.393- 394. i
- Walda A.L., Camm A.J., deRuyter H. et al. Effect of d-Sot'alol on mortality mpatients widi left ventricular dysfunction after recent and remote myocardialiinfarction. The SWORD Investigators. //Lancet.- 1996.- 348.- 7−12.
- Werko L. Atrial Fibrillation: introduction. //In: Olsson S.B., Allessie M.A., Campbell R.W., editors. Atrial Fibrillation: Mechanisms and Therapeutic Strategies. — Armonk. NY. — Futura Pub,: 1994. — 1−13.
- Wichter Т., Borggrefe M., Haverkamp W., et al. Efficacy of antiarrhythmic drugs' i in patients with arrhythmogenic right ventricular disease: Results in patients withinducible and noninducible ventricular tachycardia. //Circulation.-1992.- 86.- 29.
- Wolf P.A., Abbot R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in elderly: The Framingham study.//Arch Intern Med.-l937.-147.-1561−1564.
- Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. //Stroke. 1991. — 22. — 983−938.
- Young G.D., Kerr C.R.,' Mahama R., et al. Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. //Am. J. Cardiol.- 1994.- 73.- 677.